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Research Article
Automated integration of monolith-based
protein separation with on-plate digestion for
mass spectrometric analysis of esophageal
adenocarcinoma human epithelial samples
A unique approach of automating the integration of monolithic capillary HPLC-based
protein separation and on-plate digestion for subsequent MALDI-MS analysis has
been developed. All liquid-handling procedures were performed using a robotic mod-
ule. This automated high-throughput method minimizes the amount of time and
extensive labor required for traditional in-solution digestion followed by exhaustive
sample cleanup and analysis. Also, precise positioning of the droplet from the capillary
HPLC separation onto the MALDI plate allows for preconcentration effects of analytes
for improved sensitivity. Proteins from primary esophageal Barrett’s adenocarcinoma
tissue were prefractionated by chromatofocusing and analyzed successfully by this
automated configuration, obtaining rapid protein identifications through PMF and se-
quencing analyses with high sequence coverage. Additionally, intact protein molecular
weight values were obtained as a means to further confirm protein identification and
also to identify potential sequence modifications of proteins. This simple and rapid
method is a highly versatile and robust approach for the analysis of complex pro-
teomes.
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1 Introduction
The immense complexity of the human proteome [1]
presents a great challenge that requires the analysis of
large numbers of proteins [2]. Therefore, it is important
that proteomic methodologies should be simple, auto-
mated, and versatile for rapid and reproducible analysis
[3]. 2-DE [4] is still the most widely utilized method for
large scale proteomics applications, where in-gel
digestion of each protein spot is analyzed by sub-
sequent ESI- or MALDI-based MS analysis. Despite
development of robotic systems for gel-spot picking
and excision [5–7], 2-DE coupled with MS remains dif-
ficult and time-consuming due to extensive sample
cleanup and digestion of a few hundred to several
thousands of spots that may be present in a sample
representing the human proteome.
Recently, the integration of HPLC with offline fraction
collection for MALDI-MS analysis has received attention
[8, 9] and has been applied to several systems [10–13].
LC/MALDI has also proven useful for unique applications
and has been demonstrated to be useful in quantitative
studies [14] and in the characterization of post-transla-
tional modifications (PTMs) [15] of proteins. In experi-
ments utilizing LC/MALDI and applied to complex bio-
logical mixtures, proteins have been exclusively analyzed
by enzymatic digestion of whole cell lysates [16–20] using
sequential coupling of ion exchange and RP-HPLC
separations. Although this shotgun proteomics approach
is useful for a comprehensive analysis on a global scale
[21], the results can be misleading, where the complexity
of samples may result in false positive identifications
when only a small number of peptides are matched [22]. It
was previously shown that proteome analysis performed
at the level of intact proteins [23] through 2-D liquid phase
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separations can help avoid such problems, where each of
the protein fractions was further examined in detail and
compared with intact molecular weight (MW) analysis
[24–27]. This concept was used to develop a novel meth-
od that integrates monolithic HPLC separation of intact
proteins with on-MALDI plate tryptic digestion [28] for
rapid identification of proteins. It has been recently
applied to a human breast cancer cell line [29], where
lengthy experimental procedures required by in-solution
digestion were greatly minimized. Also, unique char-
acteristics of the monolith [30–32] as a separation medi-
um, including high recovery and rapid separation speed
[33, 34], were found to be ideally suited for the purpose of
LC/MALDI analysis.
Automation of the sample-handling process is an impor-
tant issue to be considered in proteomics in order to
develop a truly high-throughput methodology facilitating
the analysis of large numbers of proteins [35]. An auto-
mated integration of HPLC with offline fraction collection
for MALDI-MS analysis has been attempted previously in
several studies for the analysis of protein digests [10,
36]. In the present studies, we focus on the advance-
ment of this method by automation of all liquid-handling
procedures. The proteins from human esophageal ade-
nocarcinoma [37, 38] a cancer type that is demonstrating
an alarming increase in incidence, were analyzed to
demonstrate the versatility and applicability of this
method using whole tissue proteins. A selected set of
pH-fractionated Barrett’s cancer tissue samples was
analyzed for protein identification. HPLC/ESI-TOF MS
was performed to compare intact protein MW for further
confirmation.
2 Materials and methods
Proteins from esophageal tissue samples were sepa-
rated by chromatofocusing (CF) for pH fractionation. One
of the fractions was selected for further separation by
monolithic capillary RP-HPLC connected to the modified
nano-plotter (GeSim), equipped with xyz-robotic unit for
automatic offline peak collection. The fractions at 30 s
intervals were collected directly on the MALDI plate pre-
coated with trypsin for on-plate digestion and sub-
sequent MS analysis. A simplified LC/MALDI configura-
tion is described in Fig. 1, where all liquid-handling pro-
cedures were automated in this experiment. The same
pH fraction was also analyzed by online nonporous
(NPS) RP-HPLC/ESI-TOF MS to obtain accurate intact
protein MW values for comparison with theoretical MW
values.
2.1 Sample preparation
Patient consent was received according to guidelines set
forth by the institutional review board (IRB) of the Uni-
versity of Michigan. Tissues were collected and analyzed
from patients undergoing esophagectomy at the Uni-
versity of Michigan Health System between 1991 and
2001. Patients received no preoperative radiation or
chemotherapy. Each esophageal adenocarcinoma tumor
specimen was immediately frozen in liquid nitrogen and
stored at 2807C. Cryostat sectioning of all tumors were
performed and only portions of tumors containing .80%
tumor cellularity were utilized for subsequent protein iso-
lation.
Figure 1. A simplified descrip-
tion of automated LC/MALDI
configuration constructed by
modifying nano-plotter (not in
scale) for all liquid-handling pro-
cedures.
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2.2 Cell lysis and buffer exchange
A 200 mg of tissue sample was lysed with 2 mL of lysis
buffer which consisted of 7.5 M urea, 2.5 M thiourea,
4% n-octyl-D-glucopyranoside (OG), 10 mM tris(2-car-
boxyethyl)phosphine, 10% glycerol, 50 mM Tris (all from
Sigma, St. Louis, MO), and 40 mL protease inhibitor solu-
tion (one tablet in 1 mL PBS buffer, Roche, Indianapolis,
IN). Samples were then homogenized, vortexed fre-
quently for 1 h at room temperature, and centrifuged at
30 000 rpm for 70 min at 47C. The collected supernatant
was subjected to buffer exchange against CF start buffer
using a PD-10 G-25 column (Amersham Biosciences,
Piscataway, NJ). Bradford protein assay kit (BioRad, Her-
cules, CA) was used to quantify the amount of proteins in
mixtures. The buffer-exchanged protein mixtures were
stored at 2807C until further use.
2.3 CF separation
CF separation was performed on an HPCF-1D column
(2.1 mm id6250 mm length, Beckman Coulter, Fullerton,
CA) using a Beckman System Gold HPLC. Prior to sample
loading, the column was equilibrated with a start buffer
containing 25 mM Bis–Tris propane (Sigma), 6 M urea,
and 1% OG, where its pH was adjusted to pH 7.4 with
saturated iminodiacetic acid solution (Sigma). Proteins
(ca. 4.5 mg) were loaded to the elution buffer at pH 4.0
containing 10% Polybuffer 74 (Amersham Pharmacia),
6 M urea, and 1% OG at a flow rate of 0.2 mL/min. A lin-
ear pH gradient was generated so that proteins eluted off
according to their pI for detection at 280 nm. Accurate pH
was measured online by a postdetector pH electrode
(Lazar Research Laboratories, Los Angeles, CA) for frac-
tion collection at every 0.2 pH unit in the range of pH 7.0–
4.0.
2.4 Online NPS-RP-HPLC/ESI-TOF MS for intact
protein molecular weight determination
Fractions obtained from CF were subjected to NPS-RP-
HPLC separation using an ODSIII-E column (4.6 mm
id633 mm L, Eprogen, Darien, IL) packed with 1.5 mm
NPS silica. The column was maintained at 607C by a col-
umn heater (model 7971, Jones Chromatography, Reso-
lution Systems, Holland, MI) to perform separation at a
flow rate of 0.5 mL/min, where 40% was split into an ESI-
TOF MS (LCT Premier, Waters/Micromass, Milford, MA).
Formic acid (0.5%, Sigma) was added postsplitter using a
syringe pump (Harvard Apparatus, Holliston, MA). The
remainder of the flow was monitored at 214 nm (detector
model 166, Beckman Coulter) for offline peak collection
using a fraction collector (model SC100, Beckman Coul-
ter) controlled by an in-house acquisition program. A
mobile phase system of A and B was comprised of
0.1% TFA (J. T. Baker, Phillipsburg, NJ) in purified DI
water (Millipore RG system, Bedford, MA) and ACN
(Sigma), respectively. The gradient profile was as follows:
5–15% B in 1 min, 15–25% B in 2 min, 25–31% B in
3 min, 31–41% B in 10 min, 41–47% B in 3 min, 47–
67% B in 4 min, and 67–100% B in 1 min. The capillary
voltage for electrospray was set at 3200 V, sample cone
at 35 V, extraction cone at 3 V, and reflectron at 750 V.
Desolvation temperature was maintained at 3307C and
source at 1307C with desolvation gas flow of 650–800 L/h.
Intact protein MW was obtained by automatic deconvo-
lution using Protein Trawler software (BioAnalyte, Port-
land, ME).
2.5 Monolithic capillary HPLC for protein
separation
The preparation of copolymerized styrene and divi-
nylbenzene monolithic capillary columns (200 mm
id660 mm L) was performed according to procedures
described elsewhere [33]. A capillary pump (Ultra-Plus II
MD, Micro-Tech Scientific, Vista, CA) was used for
separation. The capillary column was directly mounted on
a microinjector with a 500 nL internal sample loop (Valco
Instruments, Houston, TX). The capillary HPLC separation
was controlled at 607C with an in-house column heater.
The flow from the solvent delivery pump was split pre-
column to generate a flow rate of ca. 2.5 mL/min through
the monolithic columns. A mobile phase system of two
solvents was used, wherein solvents A and B were com-
posed of 0.05% formic acid in HPLC-grade water (Fisher
Scientific, Hanover Park, IL) and ACN, respectively. A lin-
ear gradient of 0–100% B in 18 min was applied and held
at 100% B for 3 min.
2.6 Automated integration of protein separation
and on-MALDI plate enzymatic digestion
A syringe pump was interfaced with an xyz-module of
Nano-Plotter 2.0 piezoelectric pipetting system (GeSiM,
Großerkmannsdorf, Germany) by a capillary tubing in
order to precoat the MALDI plate with 0.5 mL of TPCK-
modified trypsin solution of 0.15 mg/mL (Promega, Madi-
son, WI) into each spot. Prefractionated esophageal tumor
proteins at pH 5.6–5.8 were loaded onto a monolithic
capillary column for separation, where the connecting
capillary tubing off the column was interfaced directly to
the print head of the nano-plotter. An instrument controller
program written in nano-plotter language (NPL) was used
to control the print head for precise movements along the
x, y, and z axes for automatic control over the designated
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fraction deposition time of 30 s intervals onto the MALDI
plate. Fraction collection was performed in a real-time
mode with proper calibration. Following the protein col-
lection onto each trypsinized spot, 0.5 mL of 50 mM
ammonium bicarbonate (Sigma) was automatically added
to the top layer of each spot using a syringe pump and the
plate was maintained at room temperature for digestion
for ca. 10 min. Then, 0.5 mL of 0.1% TFA was added to
each spot to halt digestion, followed by addition of 0.5 mL
of a-cyano-4-hydroxycinnamic acid (a-CHCA, Sigma)
matrix solution prepared by diluting saturated a-CHCA
with 60% ACN/0.1% TFA at a 1:4 ratio. The internal
standards of angiotensin I, adrenocorticotropic hormone
(ACTH) fragment 1–17, and ACTH fragment 18–39 (all
from Sigma) were included to have a final concentration of
50 fmol in every spot.
2.7 MALDI-TOF MS analysis and database
searching
The MALDI-TOF MS analysis was performed on a Tof-
Spec2E (Waters/Micromass) equipped with delayed
extraction in reflectron mode using a 337 nm Nd:YAG
laser as the ionization source. The delay time was set at
520 ns, the extraction voltage at 1:1 to the source voltage
at 20 kV, and the pulse voltage at 2300 V. Each spectrum
was internally calibrated and monoisotopic peptide mas-
ses were obtained using MassLynx software version 4.0
(Waters-Micromass) for submission to the MS-Fit search
engine using Swiss-Prot database for protein identifica-
tion. The search was carried out under the species of
Homo sapiens at ,100 ppm of mass tolerance with no
limitation set for MW and pI. One missed cleavage was
allowed and the possible modifications included N-ter-
minal Gln to pyroGlu, oxidation of Met, N-terminal acet-
ylation, and phosphorylation at S, T, and Y. Protein iden-
tification was accepted as a match by filtering according
to the following parameters: MOWSE score of .103 and
sequence coverage of .20% and comparison with intact
MW values.
2.8 MALDI-TOF/TOF MS analysis and database
searching
The MALDI-TOF/TOF MS analysis was performed using a
4800 MALDI TOF/TOF analyzer (Applied Biosystems,
Foster City, CA) with a 384-well plate. A CID voltage of
2 kV was used throughout the runs. S/N threshold of 50
and 30 were used for selecting the precursor and frag-
ment peaks, respectively. The MASCOT available online
at www.matrixscience.com was used for database
searching under Swiss-Prot for Homo sapiens. Mass tol-
erances of 50 ppm and 0.3 Da were used for precursor
and fragment ions, respectively, by allowing one missed
cleavage. The same variable modifications were allowed
as in PMF analysis.
3 Results and discussion
3.1 Design of automated integration of
monolithic LC-based protein separation and
on-plate tryptic digestion
A number of different approaches have been developed
to interface HPLC and MALDI-MS. It has recently been
shown that the use of sheath gas flow around the emerg-
ing droplet of LC effluent assisted solvent evaporation,
but prevented the oxidation of analytes [18]. In another
study, a pull-down deposition method, applying an elec-
tric field to the analyte-collection device, has been
demonstrated to effectively deposit a droplet from the
HPLC [36]. This method can be particularly useful where
very small droplets are generated through nanoscale LC
to reduce droplet adhesion to the connecting tubing.
However, it may complicate the experimental platform
with the use of high voltage applied across the entire
analyte-collection device, where electrochemical reac-
tions may adversely affect MS spectra. Others reported a
pressure pulse-driven dispenser device [39] and a heated
droplet interface [40].
Figure 1 describes the schematic of the automated con-
figuration to integrate a monolithic capillary HPLC with on-
plate digestion of intact proteins for subsequent MALDI-
TOF MS analysis. This experimental configuration involves
a continuous liquid deposition through contact to the
MALDI plate for simplicity, which also proved to provide
sufficiently high precision for the purpose of this study.
Given the flow rate used for HPLC separation in our
experiment, ca. 1.2 mL from the HPLC is deposited on each
spot. Unlike nano-LC applications, this effluent volume is
considered to be sufficiently large so that droplet adhesion
to the connecting capillary is less of a concern, eliminating
the need for a sophisticated platform for liquid collection.
Figure 2 shows a very close proximity between the inter-
face of LC effluent and the MALDI plate, which measures
ca. 0.1 mm. Compared to the protein collection and liquid
deposition performed manually in our previous study [29],
this automated device can ensure highly precise posi-
tioning of liquid deposition into a very small area of the
spot surface. This provides a method enhancing protein
concentration for highly efficient digestion, therefore,
detection for improved sensitivity for MS analysis. This
added advantage can be particularly useful for analyzing
proteins present in low abundance or limited amounts of
sample.
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Figure 2. Automated LC/
MALDI interface where proteins
separated by capillary mono-
lithic HPLC are deposited di-
rectly onto the MALDI target
plate precoated with trypsin.
The optimal time interval for analyte collection will be de-
pendent on the complexity of the samples [17]. Although
a 30 s interval was used for protein collection time in this
study, our automation device can be programed for
shorter analyte deposition time down to several seconds
or less that may be necessary for the analysis of very
complex proteomes. The flexibility of the automated sys-
tem allows multiple numbers of the MALDI plates of
varying sizes to be accommodated, which can further
enhance throughput of this method.
3.2 Identification of human esophageal cancer
tissue proteins
In our previous study, human breast cancer cell line pro-
teins prefractionated by a Rotofor device of preparative
scale were chosen as a model to show the applicability of
LC/MALDI to biological mixtures [29]. However, the use of
Rotofor device is less appropriate when the samples to be
analyzed are limited in quantity, as it is often the case for
human tissue samples. Recently, the usefulness of CF
[41] as a first-dimensional fractionation has been suc-
cessfully demonstrated for the analysis of various human
cancer proteomes [24, 25]. In addition to reducing the
complexity of samples, it is important to note that experi-
mental pI values of proteins can be monitored online by
CF so that the presence of possible PTM can be asses-
sed by comparing to theoretical pI values [42]. In this
experiment, we extended the application of the LC/
MALDI scheme to human cancer tissue samples, where
prefractionation was performed by CF.
Proteins fractionated in the pH range of 5.6–5.8 from an
esophageal adenocarcinoma tissue sample was sub-
jected to monolithic HPLC separation interfaced with on-
plate digestion for subsequent MALDI-TOF MS and
MALDI-TOF/TOF MS analyses by automating all liquid-
handling procedures, where a limited amount of CF-frac-
tionated sample was required due to the low loading ca-
pacity of the monolithic capillary column [43]. Table 1
shows a list of proteins identified through both PMF and
intact protein MW analyses in each of the collection times,
where the LC system used a delay time of ca. 6.5 min. A
monolith-based protein separation was performed for the
collection time of ca. 20 min. As discussed in a recent
work [29], a monolithic capillary column of the small id
used in the experiment may not be the most suitable
means to separate many proteins present in complex
mixtures with high resolution and high efficiency. How-
ever, a somewhat lower resolution of protein peaks
obtained from HPLC separation does not pose a serious
problem for reliable protein identification, since sub-
sequent MS analysis can resolve the proteins.
Figure 3 illustrates a MALDI-TOF MS spectrum obtained
for the splicing factor, proline- and glutamine-rich, a large
protein of .70 kDa, that was identified with 43% of
sequence coverage, where its identified tryptic peptide
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Table 1. List of proteins identified by automated interfacing of monolithic HPLC with MALDI-TOF MS through on-plate













6.5–7 ATP synthase beta chain, mitochondrial precursor P06576 56 560
(51 736)a)
5.3 51 636 36 1.397e 1 04
9–9.5 Neuron-specific calcium-binding protein hippocalcin P84074 22 428 4.9 22 574 48 5041
10–10.5 NADH-ubiquinone oxidoreductase B16.6 subunit QP0J0 16 698 8.0 16 682 45 1.268e 1 04
11–11.5 Propionyl-CoA carboxylase beta chain P05166 58 206 7.6 57 695 30 3182
12.5–13 Paraplegin Q9UQ90 88 136 8.7 88 634 25 6.390e 1 05
13.5–14 Triosephosphate isomerase P60174 26 670 6.4 26 652 40 1.456e 1 04
Heterogeneous nuclear ribonucleoprotein A1 P09651 38 846 9.3 39 461 33 3.354e 1 05
14.5–15 Splicing factor, proline- and glutamine-rich P23246 76 150 9.5 75 490 43 1.113e112
15–15.5 Aldo-keto reductase family 1 member C3 P42330 36 845 8.1 36 886 52 2.008e 1 07
16–16.5 Calgranulin B P06702 13 242 5.7 13 816 66 8.249e 1 04
17–17.5 Lymphoid-enhancer-binding factor 1 Q9UJU2 44 201 6.9 44 549 20 1.104e 1 04
18–18.5 HLA class I histocompatibility antigen Q29718 40 421 5.7 40 195 35 1.815e 1 04
18.5–19 Aldehyde dehydrogenase 1A1 P00352 54 862 6.3 54 862 26 6.096e 1 04
19–19.5 39S Ribosomal protein L45 Q9BRJ2 35 351 9.1 35 214 26 4949
19.5–20 Tumor necrosis factor receptor superfamily member
11B precursor
O00300 46 041 8.7 45 799 32 1.943e 1 04
Cytokine-inducible SH2-containing protein Q9NSE2 28 663 6.5 28 635 47 1.415e 1 04
21–21.5 MAP kinase-interacting serine/threonine kinase 1 Q9BUB5 51 343 6.3 50 686 38 2.607e 1 04
22.5–23 Spindlin (ovarian cancer-related protein) Q9GZT2 27 077 5.8 27 246 30 1.059e 1 05
23.5–24 Transgelin-3 Q9UI15 22 473 6.8 22 878 38 6968
24.5–25 Alcohol dehydrogenase P14550 36 573 6.3 36 531 25 1.415e 1 04
25–25.5 Cyclin H P51946 37 644 6.7 37 533 43 2496
26.5–27 Peptidyl-prolyl cis–trans isomerase Q13451 51 213 5.7 50 686 31 4.837e 1 04
a) The number in parentheses indicates theoretical MW of the truncated form.
Figure 3. MALDI-TOF MS spectrum (unprocessed) obtained for the splicing factor, proline- and glutamine-rich, from an
esophageal tissue sample. * Indicates peptides identified by monolithic LC/MALDI scheme through on-plate digestion.
Refer to Table 2 for information regarding each peptide.
sequences are summarized in Table 2. As shown in
Table 1, relatively high sequence coverage was obtained
for most of the proteins and this is considered to be pri-
marily due to minimal sample transfers associated with
direct LC/MALDI interface to prevent sample loss. Also,
compared to traditional in-solution digestion, it appears
that protein enrichment effects obtained through a small
spot size due to precise control of liquid-handling com-
bined with a large surface area for enzymatic reactions
provided by precoated trypsin perhaps resulted in more
efficient digestion. Also, reduced trypsin autolysis relative
to in-solution digestion may be expected due to trypsin
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Table 2. A list of sequenced tryptic peptides identified from splicing factor, proline- and glutamine-rich, where peptides










770.3267 770.3321 594 599 0 EESYSR
830.4011 830.4484 543 548 1 QEELRR
830.4011 830.4484 542 547 1 RQEELR
*869.3300 869.3650 600 606 0 MGYMDPR
886.4747 886.4998 400 407 0 AVVIVDDR
1120.4904 1120.5210 682 693 0 GMGPGTPAGYGR
*1143.5992 1143.6275 366 376 0 FATHAAALSVR
*1170.5725 1170.5036 1Met-ox 600 608 1 MGYMDPRER
1235.5787 1235.5149 PyroGlu 1Met-ox 582 590 1 QREMEEQMR
1235.5787 1235.6497 287 296 1 RPGEKTYTQR
1245.6538 1245.6955 414 425 0 GIVEFASKPAAR
*1252.5765 1252.5414 1Met-ox 582 590 1 QREMEEQMR
*1252.5765 1252.6214 320 330 0 YGEPGEVFINK
*1267.5986 1267.6217 33 44 0 SPPPGMGLNQNR
*1341.6605 1341.6664 667 681 0 FGQGGAGPVGGQGPR
*1572.7620 1572.7263 549 560 1 MEELHNQEMQKR
*1572.7620 1572.7263 548 559 1 RMEELHNQEMQK
*1743.8246 1743.8951 343 358 1 ALAEIAKAELDDTPMR
*1762.7778 1762.7825 480 493 0 FAQHGTFEYEYSQR
*1807.8894 1807.8241 1PO4 664 681 1 TERFGQGGAGPVGGQGPR
*1807.8894 1807.9118 299 314 0 LFVGNLPADITEDEFK
*1963.9795 1964.0129 299 315 1 LFVGNLPADITEDEFKR
*2264.9968 2264.9647 1PO4 519 536 0 LESEMEDAYHEHQANLL
*2370.1633 2370.2253 212 236 0 MPGGPKPGGGPGLSTPGGHPKPPHR
*2403.0925 2403.1356 246 267 0 QHHPPYHQQHHQGPPPGGPGGR
*2428.0911 2428.1203 517 536 1 DKLESEMEDAYHEHQANLLR
*2639.1956 2639.2993 377 399 0 NLSPYVSNELLEEAFSQFGPIER
*3195.3171 3195.4372 631 663 0 FPPLGGGGGIGYEANPGVPPATMSGSMMGSDMR
*3467.1528 3467.3260 2Met-ox 3PO4 631 663 0 FPPLGGGGGIGYEANPGVPPATMSGSMMGSDMR
immobilization [44] on the plate to generate less compli-
cated mass spectra for unambiguous interpretation. In
order to further confirm the protein identification proce-
dures, LC/MALDI-based sequencing analysis was per-
formed using MALDI-TOF/TOF MS. Figure 4 shows an
example for one of the proteins in Table 1, calgranulin B,
where one of its tryptic peptides, NIETIINTFHQYSVK (11–
25) has been successfully sequenced. This protein was
identified with .50% of sequence coverage through se-
quencing analysis.
Also, since proteins are sufficiently separated from each
other for direct deposition onto the MALDI target plate to
be confined into a very small spot size with minimal sam-
ple loss expected, several less abundant proteins were
identified in this work, such as cyclin H [45] in Table 1.
Another protein, MAPK-interacting serine/threonine
kinase 1 [46], activated by phosphorylation, is also known
to be expressed at low levels. It would be difficult to
detect these proteins using a traditional proteomics
approach, where sample loss due to sample-handling
procedures is inevitable.
In addition to helping to confirm protein identifications
determined by PMF and sequencing analyses, intact
protein MW values were obtained separately by NPS-RP-
HPLC/ESI-TOF MS for comparison to theoretical MW
values with excellent agreement, as shown in Table 1. Al-
though the LC/MALDI method alone can provide highly
confident protein identification due to relatively high
sequence coverage, the usefulness of intact MW values
can be observed from a close examination of several
proteins. For instance, the splicing factor, proline- and
glutamine-rich, is annotated with two distinct isoforms A
and F (accession nos. P23246-1 and P23246-2, respec-
tively) that slightly differ in amino acid compositions in the
region of 663–707 to result in the isoform A being larger
than the isoform F by ca. 4000 Da (www.expasy.org).
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Figure 4. MALDI-TOF/TOF MS spectrum for a tryptic peptide NIETIINTFHQYSVK (11–25) of calgranulin B.
Protein identification by PMF or tandem MS-based se-
quencing analysis is solely based on partial sequence
coverage of proteins, where sequence variations, such as
truncation and isoforms, are often undetected. In our
experiment, however, comparison between theoretical
and experimental intact protein MW allows us to conclude
that it is likely that the isoform A of splicing factor, proline-
and glutamine-rich, is present in the esophageal tumor
sample. Also, significant deviation observed between the
experimental and theoretical protein MW values can sug-
gest the presence of possible modifications in certain
proteins. An example can be found from ATP synthase
beta chain that becomes truncated by the loss of transit
peptide sequence upon entry into mitochondria, where
this can also be explained by an excellent agreement be-
tween its theoretical intact MW value and experimental
MW value, as shown in Table 1. A close match between
theoretical and experimental MW values of all proteins in
Table 1 further confirms the protein identification obtained
by PMF analysis, where slight deviations can suggest the
presence of potential PTM [24].
4 Concluding remarks
We have developed a novel method that automates the
integration of monolithic capillary HPLC separation of
intact proteins and on-plate enzymatic digestion for
MALDI-based MS analysis. The method is shown to be
highly versatile and robust and is suitable for the analysis
of complex proteomes, as successfully demonstrated for
the analysis of esophageal tissue proteins. It is important
to emphasize that the current study analyzed the pro-
teome at the protein level, unlike the majority of previous
LC/MALDI work performed by shotgun proteomics that
may result in ambiguous identifications due to the com-
plexity of mixtures upon digestion of a large number of
proteins. Based on the measured intact protein MW
values and substantially higher protein sequence cover-
age from the protein-based LC/MALDI, compared to
shotgun-derived LC/MALDI, it is likely that the developed
method can help analyze PTM or other sequence varia-
tions. Although the analysis of complex proteomes is
often performed by ESI-based MS, integration of protein
separation directly to MALDI is an effective means to
solve compatibility issues with various LC solvent com-
positions and contaminants to which the ESI process is
substantially less tolerant.
Automated coupling of LC-based protein separation for
direct on-plate enzymatic digestion is an attractive means
to realize high-throughput proteomics, where the process
can be fully automated and enhance reproducibility.
Another distinct advantage includes accurate control of
the spot surface area upon deposition that allows for the
analysis of low-abundance proteins by enrichment of
© 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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analytes [47]. This is essential in proteomics studies,
where a wide dynamic range of protein concentration
presents a great challenge. Considering that the droplet
size is dependent on the surface tension and viscosity of
the solution [48], further development is ongoing to
diminish the spot diameter. The method has potential to
become even more powerful when protein identification
through automated software analysis can be combined.
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